Outcomes
SECONDARY
The primary study outcome was biomedical prevention coverage, defined as the number of months during which a participant reported taking any PrEP or PEP pills divided by the number of months assessed. Biomedical prevention coverage during periods of self‐reported HIV risk was a pre‐specified secondary endpoint, compared between arms. We additionally report on HIV seroconversions, defined as any reactive HIV self‐test or HIV rapid test (per national testing algorithm) with confirmatory HIV RNA testing.